4
Changes in Ownership
GeneDx Holdings Corp. Filed Acc 0001689575-25-000013
CHIEF EXECUTIVE OFFICER sold 2,158 shares at an average $136.54 ($294,654)
- CHIEF EXECUTIVE OFFICER acquired 3,874 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2025-10-29 | Option exercise | +3,874 | 5,594 | D | ||
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2025-10-29 | Sale | −2,154 | $136.54 | $294,107 | 3,440 | D |
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2025-10-29 | Sale | −4 | $136.75 | $547 | 3,436 | D |
| Derivatives | |||||||
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2025-10-29 | Option exercise · Restricted Stock Unit | −3,874 | 7,748 | D | ||
| Open-market sales · 2,158 sh · avg $136.54 · $294,654 | |||||||
Loading xslF345X05/form4-10312025_081058.xml…